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Background: This study aimed to evaluate the effect of extended olanzapine, 
clozapine and haloperidol administration on NMDA-R subunit immunoexpression in 
the rat neocortex and diencephalon. 
 
Methods: To explore NR1, NR2A and NR2B subunit protein 
expression,densytometric analysis of immunohistochemically stained brain slices was 
performed. 
Results: Interestingly, all neuroleptics caused a downregulation of NMDA-R subunit 
expression in the thalamus but increased the level of NR1 in the hypothalamus. 
Olanzapine upregulated hypothalamic NR2A expression, while clozapine and 
haloperidol decreased hypothalamic levels.We observed no significant changes in 
NR2B immunoreactivity. None of the studied medications had significant  influence 
on NMDA-R subunit expression in the neocortex. 
 
Conclusions:  Neuroleptic-induced reduction in the expression of thalamic NMDA-R 
subunits may play an important role in the regulation of glutamatergic transmission 
disorders in cortico–striato–thalamo–cortical loop in schizophrenia. A decrease in 
NMDA signaling in this region after long-term neuroleptic administration may also 
cautiously explain the incomplete effectiveness of these drugs in the therapy of 
schizophrenia-related cognitive disturbances.  
 
 















It has  been established that during schizophrenia there are changes in NMDA 
receptor (NMDA-R) subunit composition in various regions of the brain [1-4, Paoletti 
and Neyton 2007]. However, current results are often inconsistent and our 
understanding of the influence of neuroleptics on NMDA-R expression remains 
incomplete. Nevertheless, on the basis of this data we can still try to create a 
hypothetical model of NMDA-R subunit expression changes in patients suffering from 
schizophrenia. In this model, NR1 subunit expression decreases in majority of brain 
structures of schizophrenia patients. Accordingly, these dysfunctions result from an 
NMDA-R dependent deficit in glutamatergic transmission in certain forebrain areas, 
such as the prefrontal cortex (PFC) and hippocampus [5-8]. The NMDA receptors 
indirectly regulate dopamine release in the brain cortex, suggesting that the 
dopaminergic hypofunction, typical in schizophrenia, is secondary to glutamatergic 
action [9]. Alternatively, dopaminergic receptors participate in the regulation of 
NMDA-R expression [10], and therefore, a final consensus on the sequence of 
signaling events underlying schizophrenia remains open. The ionotropic NMDA-R is 
a heterotetramer, composed of one mandatory subunit NR1, and three different 
subunits: NR2, NR3 and NR4 [11,12]. At present, eight splice variants of subunit 
NR1, and at least four classes of the subunit NR2: A, B, C and D have been 
identified. In patients suffering from schizophrenia, NR1 and NR2A subunit 
expression decreases in dorso-lateral PFC [13, 14]. Transport of NR2B subunits is 
also disturbed, a lack of which can in turn impair NMDA-R function [15]. In frontal and 
occipital cortex there is an increase of NR2A subunit expression [16]. On the other 
hand, in the temporal cortex an increase of the number of NR2B subunits has been 
observed [17]. NR1 subunit expression is probably diminished in the thalamus [16] 
with simultaneous increase of the number of NR2B subunits in the dorso-medial area  
[18]. However, some studies have revealed no abnormalities in the thalamus [17]. In 
the hippocampus NR1 subunit expression decreases, while formation of NR2B 
subunits probably increases [19]. Moreover, the number of NMDA-Rs increases in 
putamen [20]. As the NR1 subunit is present in all NMDA-R, the results concerning 
putamen can be indirectly interpreted as an overall decrease in the number of NR1 
subunits. Similarly, expression of NR1 subunit in substantia nigra is probably 
decreased in schizophrenia [16]. Described changes of NMDA-R subunit composition 
can result from disease pathogenesis or from the influence of neuroleptics. Indeed, 
antipsychotics can change NMDA-R subunit gene expression and lead to 
modifications of receptor function [21 We previously examined an effect  of chronical 
treatment with haloperidol, clozapine and olanzapine on NMDA-R subunits 
expression in the rat hippocampus [22]. In the present article we aim to report and 
discuss the effect of these  neuroleptics on NMDA receptor composition in the rat 
hypothalamus, thalamus and neocortex. It is especially worth mentioning that 
haloperidol is a classical neuroleptic with a wide spectrum of unfavorable dyskinetic 
and cardiac side effects (Leucht et al. 2013, Stracina et al. 2015), while olanzapine 
and clozapine are new generation atypical medications which are more suitable in 
drug resistant schizophrenia (Wahlbeck et al. 2000, Duggan et al 2003., Essali et al. 
2009). In the context of this, comparing potential effects of these drugs on NMDA-R 
immunoexpression in various brain regions seems to be relatively novel and valid. 
 
 
Materials and methods 
 Adult (5 month old, 210-240 grams weight) male Sprague-Dawley rats from Medical 
University of Silesia Experimental Centre were housed at 220C with regular 12/12 
light-dark cycle and access to standard Murigran chow and water ad libitum.  
Four groups of animals (n=6) received either control vehicle, haloperidol (1 mg 
/kg/day), clozapine (20 mg/kg/day) or olanzapine (10mg/kg/day) by intraperitoneal 
injection for 4 weeks. Three hours after the last drug administration, rats were 
anaesthetized with isoflurane and their brains removed and fixed in 4% 
paraformaldehyde PBS (pH 7.2-7.4). 7 μm thick sections were cut on a microtome 
(Leica Microsystems, Germany) in the coronal plane (-3.30 to -3.80 from bregma, 
according to Paxinos & Watson’s The Rat Brain in Stereotaxic Coordinates).  
Sections were blocked with 5% goat serum and incubated with the following rabbit 
polyclonal primary antibodies against the NMDA receptor subunits; anti-NR1 (1:1500; 
AB17345), anti-NR2A (1:500; AB14596) and anti-NR2B (1:400; AB65875) were 
purchased from Abcam Company, Cambridge, UK. 
Primary antibodies were followed by biotynylated goat anti-rabbit secondary antibody, 
and then visualized via avidin-biotin-horseradish peroxidase complex (Vectastain 
ABC kit, Vector Labs), and 3,3’-diaminobenzidine. Sections were mounted on gelatin-
coated glass slides, dehydrated and coverslipped. 
The same level of cortical, thalamic and hypothalamic sections were chosen from 
each slide, and three standarized areas were studied (Fig 1.). The relatively poorly 
investigated parietal cortex was examined. The hypothalamic frame contained 
ventro- and dorsomedial (VMH, DMH) as well as paraventricular nuclei (PVN) and 
lateral area (LH). In the thalamus we focused on the main laterodorsal and 
ventrobasal nuclei involved in the crucial sensory processing. The immunoreactivity 
of NR1, NR2A and NR2B, containing cells in the randomly selected regions, were 
measured as the integrated optical density (IOD) and a mean ± SEM was calculated. 
The data were collected and analyzed using Nikon optic systems and software Image 
ProPlus (Media Cybernetics, USA). Statistical analyses were performed using 






Following neuroleptic treatment, changes in rat NMDA-R subunit expression were 
greatly dependent on the  area of rat brain analyzed. In the thalamus each 
neuroleptic treatment caused a decrease in expression of all three NMDA subunits 
examined, most notably the general subunit - NR1. Interestingly olanzapine and 
clozapine caused equivalent reductions in each NMDA subunit (Fig. 2B, Fig 3.). In 
the hypothalamus all examined neuroleptics increased NR1 expression and also, in 
the case of olanzapine administration, we observed increased NR2A expression (Fig. 
2A and B). However, treatment with clozapine and haloperidol caused reduced NR2A 
subunit expression in the hypothalamus. No significant changes in NR2B expression 
were observed in this region (Fig. 2A and B.) In the cortex, drug treatment caused an 
increased trend in NR1 expression, but the result was not statistically significant. 
Moreover, none of the studied  antipsychotics had significant  influence on NR2A and 











Collectively, these results suggest that the described neuroleptics inhibit the 
expression of NMDA receptors in the thalamus, which in turn can decrease the 
activity of the thalamic glutamatergic system. Alternatively, the NMDA-R subunit 
expression changes in the hypothalamus suggest an increase of glutamatergic circuit 
activity in this structure. In our analysis, we focused on the expression of the receptor 
subunits via protein quantification. Although, this may be a distinct limitation, we 
decided not to analyze expression at the mRNA level, given previous studies [23] and 
since changes at the mRNA level are rather difficult to interpret without specific 
information related to translation of receptor molecules [14]. For this reason, in the 
present experiment, we have emphasized a necessity of immunohistochemical 
assessment of the expression of NMDA receptor protein subunits. Neuroleptic-
induced reduction of the expression of thalamic NMDA-R subunits has so far not 
been described in the literature. This effect may play an important role in the 
regulation of glutamatergic transmission disorders in cortico–striato–thalamo–cortical 
loop in the schizophrenia. Decreased expression of the NMDA-R subunits in the 
thalamus after neuroleptic administration may correspond with our previous results 
reporting that all studied drugs decreased the number of NMDA receptor molecules 
in the CA1 and CA2 hippocampal areas [22]. Interestingly, treatment with a potent 
NMDA-R antagonist phencyclidine (PCP) markedly increased c-fos expression in the 
rat centromedial and mediodorsal thalamic nuclei as well as in the amygdala (Celada 
et al. 2013). Clozapine administration completely reversed the elevation in firing rate 
produced by PCP in thalamic and PFC glutamatergic neurons (Kargieman et al., 
2007; Santana et al., 2011). Furthermore, some  behavioural alterations after NMDA-
R blockers administration in rats are completely abolished by neuroleptics (Carlsson 
and Carlsson, 1989; Geyer et al., 2001). However, the neuronal pathways involved in 
these effects remains so far poorly investigated. Our results suggest cautiously, that 
the effect of neuroleptics might be based on the decrease of glutamatergic activity in 
the thalamic neurons. This downregulation may be particularly important for 
understanding the influence of antipsychotics on the cognitive symptoms of 
schizophrenia. For instance, clozapine has been shown to improve spatial memory in 
some animal models. The effects of this neuroleptic on delayed spatial alternation 
deficits in rats with NMDA-induced excitotoxic hippocampal damage was tested. The 
results obtained suggest that long-term, but not acute, drug administration enables 
animals with hippocampal dysfunction to develop new spatial learning (Bardgett et al. 
2006). It may have potential implications for the treatment of cognitive deficits in 
schizophrenic patients. 
According to the glutamatergic model of schizophrenia, dysfunction of NMDA 
receptors causes a dysfunctional hyperactivity of glutamatergic pyramidal neurons of 
the cerebral cortex and an increased glutamatergic transmission [24, 25]. 
Neuroleptics could potentially limit this hyperactivity of the glutamatergic system by 
reducing the number of receptors.  The increase of NRI expression in the 
hypothalamus may be related to the blockade of D2 receptors by neuroleptics. 
Dopaminergic D2 and NMDA receptors remain in a functional antagonistic 
relationship [26].  Chronic inhibition of D2 receptors by neuroleptics and their 
upregulation leads to the decreased expression of the NMDA-R [27]. Moreover, a 
decrease of NR2A subunit expression causes an increase in the proportion of NR2B 
regulatory subunits, which can also lead to increased activity of the NMDA receptor. 
[15]. In summary, we found that all of the examined neuroleptics increased 
glutamatergic activity in the rat hypothalamus. Results from this brain region are in 
line with results obtained by Riva et al. [28], who have demonstrated that a 3 week-
long haloperidol and clozapine administration decreased the expression of NR2A 
subunits in the hypothalamus. It should not be excluded that the effect observed may 
play an alternative role in the central mechanism of neuroleptic-dependent weight-
gain. 
 
The observed trend for an increase in NR1 subunit expression in the sensory cortex 
is consistent with the findings of Ułas et al. [29] who have seen an increase in  NR1 
expression in the rat parietal cortex after 3 weeks of haloperidol administration. The 
results of various independent studies have revealed that changes in the composition 
of NMDA subunits can be specific for particular cortex areas. In some experiments it 
was observed, that after haloperidol treatment there was  a slight increase of NR1 
expression in the rat temporal cortex. In the studies performed by Hanaoka et al. [30] 
2 week-long administration of  haloperidol and clozapine leads to a decrease of NR1 
and NR2B subunit protein level in the frontal cortex. On the other hand, clozapine 
administered for 6 months decreases the number of NR1 subunits in the dorsolateral 
part of the PFC. These above-mentioned neuroleptics cause a decrease of NR2A 
subunits expression in the rat PFC [31]. Presented changes in NMDA-R subunit 
expression in different areas of the sensory cortex suggest the regional specificity of 
the influence of neuroleptics on the NMDA receptor composition. Special attention 
should be given to the comparison of obtained results with changes of NMDA 
receptor subunit expression in patients suffering from schizophrenia. Human studies 
have revealed an increased expression of NR2B subunits in the hippocampus, 
thalamus and in some parts of the cerebral cortex. This effect is opposite to the one 
obtained in animal studies, where an inhibition of NR2B subunit expression was 
observed after exposure to neuroleptics. The data from experiments on humans 
suggests that an increase of NR2B subunits expression is related to the 
pathogenesis of schizophrenia, rather than with exact effects of neuroleptics used in 
the therapy. It may indicate the importance of the modulating influence of 
neuroleptics on the NMDA receptor composition and thereby on their activity. An 
inhibitory effect of neuroleptics on NMDA-R expression as well as the drug-induced 
reduction of thalamic glutamatergic activity could be important elements of the 
mechanism of neuroleptic anti-schizophrenic activities. A decreased NR1 
phosphorylation was also found in some other brain regions in schizophrenia patients 
[32]. Mice with mutation in the NR1 molecule exhibit an impairment in social 
behaviour [16]. However, it seems that the specific activity of the NMDA-R has mostly 
been determined via the analysis of the subunit NR2 [6,33]. Varied expression of the 
alternative subunit classes could determine a level of receptor sensitivity to different 
antipsychotic actions. Haloperidol, clozapine and olanzapine, are dopaminergic 
receptor antagonists and despite their lack of affinity to the NMDA-R, present a 
significant increase in glutamatergic transmission [14]. Some studies suggested that 
the blockage of the dopamine receptors D2 and D4 by haloperidol, cause an increase 
in phosphorylation of the NR1 subunit via protein kinase, leading to sensitization of 
the glutamate receptor [28]. However, alternative studies, demonstrate no influence 
of haloperidol on NMDA-R activity in the rat PFC [30]. Conversely, it has also been 
reported that atypical antipsychotic drugs enhance glutamatergic activity in the PFC 
[31]. In turn, clozapine, may also indirectly influence the activity of the glutamatergic 
system, by inhibiting glutamate reuptake, through a decreased expression of the 
glycine transporters, EAAT 3 and EAAT 2, in neurons and astrocytes. Perhaps, the 
observed dynamic changes in composition of NMDA-R subunits could explain 
differences in the spectrum of cognitive process modification in schizophrenic 
patients, treated with classical and atypical antipsychotic drugs [26]. A dysfunction of 
PFC has been associated with the augmented response to stress observed in 
schizophrenic patients. Interestingly, a recent report suggests that the hypofunction 
of prefrontal NMDA-Rs does not affect the sensitivity to acute stress of dopamine and 
noradrenaline projections to amygdala but impairs the acquisition of aversive memory 
(Del Arco et al. 2015). On the other hand, it is known  that schizophrenic 
patients  often show abnormal affective multisensory integration and an emotion 
recognition impairment (Van den Stock et al. 2011). We can not exclude that these 
disturbances may be associated with some deficits in glutamatergic signaling in the 
limbic structures. 
It has been also proposed that NMDA-Rs deficits in the prefronto-thalamo-cerebellar 
circuit  may play a role in the pathogenesis of schizophrenia (Andreasen et al. 1999, 
Yeganeh-Doost et al. 2011).  A study by Schmitt et al. (2010) reported that clozapine 
may be superior to haloperidol in restoring a deficit in NMDA-R subunit NR2C 
expression in the cerebellum of rats chronically treated with these neuroleptics. 
Noteworthy, there was no significant difference in the gene expression of NR1, 
NR2A, NR2B, NR2C and NR2D subunits or NMDA receptor binding between control 
animals and groups receiving drug treatment. In the current study we have 
investigated whether chronic administration of haloperidol, clozapine and olanzapine 
affects the immunoexpression of the NR1, NR2A and NR2B subunits in the rat 
hypothalamus, thalamus and PFC. We postulate that the possible changes in NMDA-
R expression among the examined neuroleptics may contribute to their different 








Our results support a hypothesis that the neuroleptic-dependent changes in 
expression of NMDA receptor subunits in the rat thalamus, may theoretically and 
cautiously explain the incomplete effectiveness of these medications in the therapy of 
cognitive dysfunctions in schizophrenia. On the other hand, the increase of 
hypothalamic glutamatergic activity may be related to common neuroleptic side 
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Fig 1. Standarized frames used for the integrated optical density (IOD) measurement 
in the examined brain regions after immunohistochemical procedure. Nissl staining. 
Scale bar: 500 m.  
 
 
Fig 2. Representative expression of NR1, NR2A and NR2B in the hypothalamus of 
control and indicated neuroleptic treated animals. The immunopositive perikarya and 
dendrites of multipolar neurons are visible (A). Scale bars: 100 m. Changes in the 
expression of NR1, NR2A and NR2B subunits in rat hypothalamus and thalamus (B.). 
Results are based on the mean values of integrated optical density (IOD), and 
expressed as percentages of control (100%) for n=6 rats. OLZ – olanzapine, KLO – 
clozapine, HAL – haloperidol. *p<0,05, **p<0,01.   
 
Fig 3. The NMDA-Rs expressing cells in the thalamus. Immunopositive perikarya and 
processes of multipolar neurons are visible. Scale bars: 100 m 
 
 
 
